Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC)
Skoulidis, F. De Langen, A. Paz-Ares, L. G. Mountzios, G. S. Curioni-Fontecedro, A. Couraud, S. Janssens, A. Rocco, D. Ohashi, K. Vincent, M. D.
Skoulidis, F.
De Langen, A.
Paz-Ares, L. G.
Mountzios, G. S.
Curioni-Fontecedro, A.
Couraud, S.
Janssens, A.
Rocco, D.
Ohashi, K.
Vincent, M. D.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Skoulidis F, De Langen A, Paz-Ares LG, Mountzios GS, Curioni-Fontecedro A, Couraud S, et al. Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003679.